BLOOD, ISSN 0006-4971, 08/2009, Volume 114, Issue 7, pp. 1374 - 1382
We showed that E mu-MiR-155 transgenic mice develop acute lymphoblastic leukemia/high-grade lymphoma. Most of these leukemias start at approximately 9 months...
CASTLEMANS-DISEASE | ACTIVATION | GENE | PHOSPHORYLATION | C/EBP FAMILY | SHIP | DIFFERENTIATION | HEMATOLOGY | TRANSCRIPTION FACTOR | EXPRESSION | MICRORNA-155
CASTLEMANS-DISEASE | ACTIVATION | GENE | PHOSPHORYLATION | C/EBP FAMILY | SHIP | DIFFERENTIATION | HEMATOLOGY | TRANSCRIPTION FACTOR | EXPRESSION | MICRORNA-155
Journal Article
Biologics : Targets & Therapy, ISSN 1177-5491, 01/2016, Volume 2016, Issue Issue 1, pp. 9 - 15
Jean L Koff, Sagar Lonial Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA Abstract: Castleman disease (CD)...
Castlemans disease | siltuximab
Castlemans disease | siltuximab
Journal Article
Netherlands Journal of Medicine, ISSN 0300-2977, 08/2018, Volume 76, Issue 6, pp. 306 - 307
Journal Article
JAMA Surgery, ISSN 2168-6254, 09/2017, Volume 152, Issue 9, pp. 887 - 888
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 04/2018, Volume 15, Issue 4, pp. 234 - 248
The IL-6/JAK/STAT3 pathway is aberrantly hyperactivated in many types of cancer, and such hyperactivation is generally associated with a poor clinical...
EPITHELIAL-MESENCHYMAL TRANSITION | SERUM INTERLEUKIN-6 LEVELS | ADVANCED SOLID TUMORS | ONCOLOGY | TRANSCRIPTION 3 STAT3 | SQUAMOUS-CELL CARCINOMA | ANTI-INTERLEUKIN-6 MONOCLONAL-ANTIBODY | PLACEBO-CONTROLLED TRIAL | MULTICENTRIC CASTLEMANS-DISEASE | SILTUXIMAB CNTO 328 | SMALL-MOLECULE INHIBITOR | Care and treatment | Immune response | Immunotherapy | Oncology, Experimental | Cellular signal transduction | Research | T cells | Health aspects | Cancer | Cell proliferation | Cell survival | Invasiveness | Stat3 protein | Lymphocytes T | Inflammation | FDA approval | Patients | Metastases | Interleukin 6 | Signal transduction | Immune checkpoint | Interleukin 6 receptors | Medical prognosis | Solid tumors
EPITHELIAL-MESENCHYMAL TRANSITION | SERUM INTERLEUKIN-6 LEVELS | ADVANCED SOLID TUMORS | ONCOLOGY | TRANSCRIPTION 3 STAT3 | SQUAMOUS-CELL CARCINOMA | ANTI-INTERLEUKIN-6 MONOCLONAL-ANTIBODY | PLACEBO-CONTROLLED TRIAL | MULTICENTRIC CASTLEMANS-DISEASE | SILTUXIMAB CNTO 328 | SMALL-MOLECULE INHIBITOR | Care and treatment | Immune response | Immunotherapy | Oncology, Experimental | Cellular signal transduction | Research | T cells | Health aspects | Cancer | Cell proliferation | Cell survival | Invasiveness | Stat3 protein | Lymphocytes T | Inflammation | FDA approval | Patients | Metastases | Interleukin 6 | Signal transduction | Immune checkpoint | Interleukin 6 receptors | Medical prognosis | Solid tumors
Journal Article
Blood, ISSN 0006-4971, 07/2011, Volume 118, Issue 2, pp. 217 - 218
Journal Article
Journal of Clinical and Diagnostic Research, ISSN 2249-782X, 2013, Volume 7, Issue 3, pp. 573 - 575
Castleman`s Disease (CD) is a rare lymphoproliferative disorder and a mesenteric location is unusual. The unicentric variety is more difficult to diagnose...
Castlemans disease | Unicentric | Mesenteric
Castlemans disease | Unicentric | Mesenteric
Journal Article
International Immunology, ISSN 0953-8178, 02/2010, Volume 22, Issue 5, pp. 347 - 352
In the late 1960s, the essential role of T cells in antibody production was reported. This led to our hypothesis that T-cell-derived soluble factors would have...
Humanized anti-IL-6R antibody | IL-6R | Gp130 | B-cell stimulatory factor-2 | IL-6 | RHEUMATOID-ARTHRITIS | INTERLEUKIN-6 TRANSGENIC MICE | JUVENILE IDIOPATHIC ARTHRITIS | SIGNAL TRANSDUCER GP130 | RESPONSE IN-VITRO | IMMUNOLOGY | IGE ANTIBODY-RESPONSE | CASTLEMANS-DISEASE | humanized anti-IL-6R antibody | ARYL-HYDROCARBON RECEPTOR | gp130 | CELL-DIFFERENTIATION | STIMULATORY FACTOR-II | Interleukin-6 - history | Animals | B-Lymphocytes - immunology | Research - history | History, 21st Century | History, 20th Century | Humans | Interleukin-6 - immunology
Humanized anti-IL-6R antibody | IL-6R | Gp130 | B-cell stimulatory factor-2 | IL-6 | RHEUMATOID-ARTHRITIS | INTERLEUKIN-6 TRANSGENIC MICE | JUVENILE IDIOPATHIC ARTHRITIS | SIGNAL TRANSDUCER GP130 | RESPONSE IN-VITRO | IMMUNOLOGY | IGE ANTIBODY-RESPONSE | CASTLEMANS-DISEASE | humanized anti-IL-6R antibody | ARYL-HYDROCARBON RECEPTOR | gp130 | CELL-DIFFERENTIATION | STIMULATORY FACTOR-II | Interleukin-6 - history | Animals | B-Lymphocytes - immunology | Research - history | History, 21st Century | History, 20th Century | Humans | Interleukin-6 - immunology
Journal Article
Nature Reviews Cancer, ISSN 1474-175X, 10/2010, Volume 10, Issue 10, pp. 707 - 719
Kaposi's sarcoma (KS) is the most common cancer in HIV-infected untreated individuals. Kaposi's sarcoma-associated herpesvirus (KSHV; also known as human...
ONCOLOGY | PROTEIN-COUPLED RECEPTOR | ACTIVE ANTIRETROVIRAL THERAPY | PRIMARY EFFUSION LYMPHOMA | MICROVASCULAR ENDOTHELIAL-CELLS | INTERFERON REGULATORY FACTOR-1 | AIDS-RELATED MALIGNANCIES | ACQUIRED-IMMUNODEFICIENCY SYNDROME | NF-KAPPA-B | MULTICENTRIC CASTLEMANS-DISEASE | RENAL-TRANSPLANT RECIPIENTS | Cell Proliferation | Herpesvirus 8, Human - pathogenicity | Cell Transformation, Neoplastic | Humans | Sarcoma, Kaposi - virology | Sarcoma, Kaposi - epidemiology | Cell Transformation, Viral | Sarcoma, Kaposi - pathology | Apoptosis | Care and treatment | Kaposi's sarcoma | Development and progression | Genetic aspects | Diagnosis | Herpesviruses | Health aspects | Risk factors
ONCOLOGY | PROTEIN-COUPLED RECEPTOR | ACTIVE ANTIRETROVIRAL THERAPY | PRIMARY EFFUSION LYMPHOMA | MICROVASCULAR ENDOTHELIAL-CELLS | INTERFERON REGULATORY FACTOR-1 | AIDS-RELATED MALIGNANCIES | ACQUIRED-IMMUNODEFICIENCY SYNDROME | NF-KAPPA-B | MULTICENTRIC CASTLEMANS-DISEASE | RENAL-TRANSPLANT RECIPIENTS | Cell Proliferation | Herpesvirus 8, Human - pathogenicity | Cell Transformation, Neoplastic | Humans | Sarcoma, Kaposi - virology | Sarcoma, Kaposi - epidemiology | Cell Transformation, Viral | Sarcoma, Kaposi - pathology | Apoptosis | Care and treatment | Kaposi's sarcoma | Development and progression | Genetic aspects | Diagnosis | Herpesviruses | Health aspects | Risk factors
Journal Article
10.
Last Resort
JOURNAL OF HOSPITAL MEDICINE, ISSN 1553-5592, 09/2019, Volume 14, Issue 9, pp. 568 - 572
Journal Article
Nature Reviews Drug Discovery, ISSN 1474-1776, 06/2018, Volume 17, Issue 6, pp. 395 - 412
Interleukin-6 (IL-6) is a pivotal cytokine with a diverse repertoire of physiological functions that include regulation of immune cell proliferation and...
DIFFERENTIATION FACTOR BCDF | TUMOR-NECROSIS-FACTOR | SYSTEMIC-LUPUS-ERYTHEMATOSUS | SELECTIVE JAK-1 INHIBITOR | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | ANTI-IL-6 RECEPTOR ANTIBODY | ANTI-INTERLEUKIN-6 MONOCLONAL-ANTIBODY | TYROSINE KINASE JAK2 | LIVED PLASMA-CELLS | PHARMACOLOGY & PHARMACY | CILIARY NEUROTROPHIC FACTOR | MULTICENTRIC CASTLEMANS-DISEASE | Care and treatment | Cellular signal transduction | Lymphoproliferative disorders | Research | Analysis | Interleukin-6 | Cytokines | Clinical trials | Rheumatoid arthritis
DIFFERENTIATION FACTOR BCDF | TUMOR-NECROSIS-FACTOR | SYSTEMIC-LUPUS-ERYTHEMATOSUS | SELECTIVE JAK-1 INHIBITOR | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | ANTI-IL-6 RECEPTOR ANTIBODY | ANTI-INTERLEUKIN-6 MONOCLONAL-ANTIBODY | TYROSINE KINASE JAK2 | LIVED PLASMA-CELLS | PHARMACOLOGY & PHARMACY | CILIARY NEUROTROPHIC FACTOR | MULTICENTRIC CASTLEMANS-DISEASE | Care and treatment | Cellular signal transduction | Lymphoproliferative disorders | Research | Analysis | Interleukin-6 | Cytokines | Clinical trials | Rheumatoid arthritis
Journal Article
JOURNAL OF VIROLOGY, ISSN 0022-538X, 10/2011, Volume 85, Issue 19, pp. 9877 - 9886
MicroRNAs (miRNAs) are small noncoding RNA molecules that function as posttranscriptional regulators of gene expression. Kaposi's sarcoma (KS)-associated...
CASTLEMANS-DISEASE | DNA-SEQUENCES | HUMAN INTERLEUKIN-6 | VIROLOGY | MAREKS-DISEASE VIRUS | HEMATOPOIETIC STEM-CELLS | ENDOTHELIAL-CELLS | GENE-EXPRESSION | LYMPHOPROLIFERATIVE DISORDER | EPSTEIN-BARR-VIRUS | TRANSGENIC MICE
CASTLEMANS-DISEASE | DNA-SEQUENCES | HUMAN INTERLEUKIN-6 | VIROLOGY | MAREKS-DISEASE VIRUS | HEMATOPOIETIC STEM-CELLS | ENDOTHELIAL-CELLS | GENE-EXPRESSION | LYMPHOPROLIFERATIVE DISORDER | EPSTEIN-BARR-VIRUS | TRANSGENIC MICE
Journal Article
International Journal of Surgical Pathology, ISSN 1066-8969, 5/2015, Volume 23, Issue 3, pp. 207 - 208
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2007, Volume 356, Issue 23, pp. 2361 - 2371
This study evaluated clinical features, organ function, and survival in a group of 374 patients with amyloid A amyloidosis. Median survival after diagnosis was...
P COMPONENT | REGRESSION | MEDICINE, GENERAL & INTERNAL | CASTLEMANS-DISEASE | PROTEIN | SCINTIGRAPHY | SERUM | AL AMYLOIDOSIS | BINDING | SECONDARY AMYLOIDOSIS | TRANSPLANTATION | Serum Amyloid A Protein - metabolism | Humans | Middle Aged | Risk Factors | Kaplan-Meier Estimate | Amyloidosis - mortality | Familial Mediterranean Fever - complications | Male | Amyloidosis - blood | Disease Progression | Arthritis - complications | Adolescent | Age of Onset | Aged, 80 and over | Adult | Female | Aged | Amyloidosis - complications | Child | Infection - complications | Kidney Failure, Chronic - etiology | Proteins | Alzheimers disease | Apolipoproteins
P COMPONENT | REGRESSION | MEDICINE, GENERAL & INTERNAL | CASTLEMANS-DISEASE | PROTEIN | SCINTIGRAPHY | SERUM | AL AMYLOIDOSIS | BINDING | SECONDARY AMYLOIDOSIS | TRANSPLANTATION | Serum Amyloid A Protein - metabolism | Humans | Middle Aged | Risk Factors | Kaplan-Meier Estimate | Amyloidosis - mortality | Familial Mediterranean Fever - complications | Male | Amyloidosis - blood | Disease Progression | Arthritis - complications | Adolescent | Age of Onset | Aged, 80 and over | Adult | Female | Aged | Amyloidosis - complications | Child | Infection - complications | Kidney Failure, Chronic - etiology | Proteins | Alzheimers disease | Apolipoproteins
Journal Article